Viemed Healthcare (VMD)
Market Price (5/16/2026): $9.34 | Market Cap: $358.9 MilSector: Health Care | Industry: Life Sciences Tools & Services
Viemed Healthcare (VMD)
Market Price (5/16/2026): $9.34Market Cap: $358.9 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20% Attractive yieldFCF Yield is 7.2% Low stock price volatilityVol 12M is 38% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Telehealth Platforms, Show more. | Weak multi-year price returns2Y Excs Rtn is -11%, 3Y Excs Rtn is -91% | Key risksVMD key risks include [1] its significant dependence on Medicare reimbursement for its core ventilator services and [2] challenges executing its growth-by-acquisition strategy. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20% |
| Attractive yieldFCF Yield is 7.2% |
| Low stock price volatilityVol 12M is 38% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Telehealth Platforms, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -11%, 3Y Excs Rtn is -91% |
| Key risksVMD key risks include [1] its significant dependence on Medicare reimbursement for its core ventilator services and [2] challenges executing its growth-by-acquisition strategy. |
Qualitative Assessment
AI Analysis | Feedback
Viemed Healthcare (VMD) stock has gained about 20% since 1/31/2026 because of the following key factors:
1. Viemed Healthcare reported strong Q4 2025 financial results in early March 2026, exceeding analyst expectations and providing upbeat guidance for 2026. The company announced an EPS of $0.14 for Q4 2025, surpassing analysts' consensus estimate of $0.12 by 16.67%. These results highlighted robust revenue growth, expanding EBITDA, and a more than doubled free cash flow, contributing to a positive bias in the stock. Additionally, the company offered upbeat 2026 revenue and EBITDA guidance, which, despite a later Q1 2026 earnings miss, was subsequently narrowed and slightly raised for full-year revenue to $312 million-$320 million, with Adjusted EBITDA reaffirmed at $65 million-$69 million.
2. The company initiated a new share repurchase program in March 2026, signaling management's confidence and enhancing shareholder value. Viemed Healthcare announced its 2026 share repurchase program around March 4, 2026. During the first quarter of 2026, the company repurchased and canceled 150,000 common shares at an average price of $9.29 per share, totaling $1.4 million. This action was seen as accretive to per-share value for continuing shareholders and a contributing factor to positive share performance.
Show more
1. Viemed Healthcare reported strong Q4 2025 financial results in early March 2026, exceeding analyst expectations and providing upbeat guidance for 2026. The company announced an EPS of $0.14 for Q4 2025, surpassing analysts' consensus estimate of $0.12 by 16.67%. These results highlighted robust revenue growth, expanding EBITDA, and a more than doubled free cash flow, contributing to a positive bias in the stock. Additionally, the company offered upbeat 2026 revenue and EBITDA guidance, which, despite a later Q1 2026 earnings miss, was subsequently narrowed and slightly raised for full-year revenue to $312 million-$320 million, with Adjusted EBITDA reaffirmed at $65 million-$69 million.
2. The company initiated a new share repurchase program in March 2026, signaling management's confidence and enhancing shareholder value. Viemed Healthcare announced its 2026 share repurchase program around March 4, 2026. During the first quarter of 2026, the company repurchased and canceled 150,000 common shares at an average price of $9.29 per share, totaling $1.4 million. This action was seen as accretive to per-share value for continuing shareholders and a contributing factor to positive share performance.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 21.9% change in VMD stock from 1/31/2026 to 5/15/2026 was primarily driven by a 12.5% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5152026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.67 | 9.35 | 21.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 255 | 287 | 12.5% |
| Net Income Margin (%) | 5.3% | 5.2% | -2.7% |
| P/E Multiple | 21.8 | 24.1 | 10.8% |
| Shares Outstanding (Mil) | 39 | 38 | 0.5% |
| Cumulative Contribution | 21.9% |
Market Drivers
1/31/2026 to 5/15/2026| Return | Correlation | |
|---|---|---|
| VMD | 21.9% | |
| Market (SPY) | 7.1% | 12.9% |
| Sector (XLV) | -5.8% | 31.2% |
Fundamental Drivers
The 44.7% change in VMD stock from 10/31/2025 to 5/15/2026 was primarily driven by a 32.1% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 5152026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.46 | 9.35 | 44.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 241 | 287 | 19.0% |
| Net Income Margin (%) | 5.8% | 5.2% | -10.4% |
| P/E Multiple | 18.3 | 24.1 | 32.1% |
| Shares Outstanding (Mil) | 40 | 38 | 2.8% |
| Cumulative Contribution | 44.7% |
Market Drivers
10/31/2025 to 5/15/2026| Return | Correlation | |
|---|---|---|
| VMD | 44.7% | |
| Market (SPY) | 9.0% | 17.3% |
| Sector (XLV) | 1.4% | 32.5% |
Fundamental Drivers
The 32.2% change in VMD stock from 4/30/2025 to 5/15/2026 was primarily driven by a 27.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302025 | 5152026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.07 | 9.35 | 32.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 224 | 287 | 27.8% |
| Net Income Margin (%) | 5.0% | 5.2% | 3.4% |
| P/E Multiple | 24.2 | 24.1 | -0.4% |
| Shares Outstanding (Mil) | 39 | 38 | 0.5% |
| Cumulative Contribution | 32.2% |
Market Drivers
4/30/2025 to 5/15/2026| Return | Correlation | |
|---|---|---|
| VMD | 32.2% | |
| Market (SPY) | 34.8% | 24.5% |
| Sector (XLV) | 5.1% | 26.4% |
Fundamental Drivers
The -13.8% change in VMD stock from 4/30/2023 to 5/15/2026 was primarily driven by a -63.6% change in the company's P/E Multiple.| (LTM values as of) | 4302023 | 5152026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.85 | 9.35 | -13.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 139 | 287 | 106.4% |
| Net Income Margin (%) | 4.5% | 5.2% | 15.9% |
| P/E Multiple | 66.3 | 24.1 | -63.6% |
| Shares Outstanding (Mil) | 38 | 38 | -1.1% |
| Cumulative Contribution | -13.8% |
Market Drivers
4/30/2023 to 5/15/2026| Return | Correlation | |
|---|---|---|
| VMD | -13.8% | |
| Market (SPY) | 84.7% | 26.3% |
| Sector (XLV) | 14.2% | 24.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| VMD Return | -33% | 45% | 4% | 2% | -7% | 28% | 22% |
| Peers Return | 4% | -15% | -8% | -24% | 38% | -16% | -28% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| VMD Win Rate | 42% | 58% | 58% | 58% | 42% | 80% | |
| Peers Win Rate | 56% | 53% | 47% | 42% | 42% | 42% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| VMD Max Drawdown | -54% | -35% | -49% | -37% | -30% | -15% | |
| Peers Max Drawdown | -33% | -44% | -52% | -42% | -36% | -55% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: A, ATEC, CERS, ALMR, POAS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/15/2026 (YTD)
How Low Can It Go
| Event | VMD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -22.0% | -18.8% |
| % Gain to Breakeven | 28.2% | 23.1% |
| Time to Breakeven | 271 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -32.4% | -9.5% |
| % Gain to Breakeven | 47.8% | 10.5% |
| Time to Breakeven | 105 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -34.2% | -24.5% |
| % Gain to Breakeven | 52.0% | 32.4% |
| Time to Breakeven | 37 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -52.5% | -33.7% |
| % Gain to Breakeven | 110.7% | 50.9% |
| Time to Breakeven | 28 days | 140 days |
In The Past
Viemed Healthcare's stock fell -22.0% during the 2025 US Tariff Shock. Such a loss loss requires a 28.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | VMD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -22.0% | -18.8% |
| % Gain to Breakeven | 28.2% | 23.1% |
| Time to Breakeven | 271 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -32.4% | -9.5% |
| % Gain to Breakeven | 47.8% | 10.5% |
| Time to Breakeven | 105 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -34.2% | -24.5% |
| % Gain to Breakeven | 52.0% | 32.4% |
| Time to Breakeven | 37 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -52.5% | -33.7% |
| % Gain to Breakeven | 110.7% | 50.9% |
| Time to Breakeven | 28 days | 140 days |
In The Past
Viemed Healthcare's stock fell -22.0% during the 2025 US Tariff Shock. Such a loss loss requires a 28.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Viemed Healthcare (VMD)
Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment (DME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company also leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), percussion vests, oxygen concentrator units, and other small respiratory equipment; and sells and rents DME and patient medical services. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management related solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.
AI Analysis | Feedback
- Imagine ResMed or Philips, but focused on the 'last mile': Viemed delivers, installs, and provides ongoing clinical support for advanced respiratory equipment directly to patients' homes.
- Think of it as DaVita for chronic respiratory patients: instead of kidney care, Viemed provides comprehensive in-home medical equipment and clinical services for conditions like COPD and sleep apnea.
AI Analysis | Feedback
- In-Home Durable Medical Equipment (DME): Provides and leases a variety of medical devices, including invasive and non-invasive ventilators, PAP machines, percussion vests, and oxygen concentrators.
- Post-Acute Respiratory Healthcare Services: Offers comprehensive management solutions for respiratory diseases, such as COPD, utilizing various therapies and equipment.
- Sleep Apnea Management Solutions: Delivers services, including in-home testing, and provides equipment like PAP machines for the diagnosis and treatment of sleep apnea.
- Neuromuscular Care and Oxygen Therapy Services: Provides specialized care and associated equipment for patients requiring neuromuscular support and oxygen therapy.
AI Analysis | Feedback
Major Customers of Viemed Healthcare (VMD)
Viemed Healthcare (VMD) primarily sells its durable medical equipment and post-acute respiratory healthcare services directly to individual patients in their homes. Based on the company description, its major customer categories include:
- Patients with Chronic Obstructive Pulmonary Disease (COPD): Individuals suffering from COPD who require non-invasive ventilation, percussion vests, and other respiratory therapies and related equipment.
- Patients requiring Sleep Apnea Management: Individuals diagnosed with sleep apnea who need Positive Airway Pressure (PAP) machines, automatic continuous positive airway pressure (APAP), bi-level positive airway pressure (BiPAP) machines, and in-home sleep apnea testing services.
- Patients needing Neuromuscular Care and Oxygen Therapy: Individuals with various neuromuscular conditions or other respiratory issues requiring invasive or non-invasive ventilation, oxygen concentrator units, and other specialized respiratory equipment and services.
AI Analysis | Feedback
nullAI Analysis | Feedback
Casey Hoyt, Chief Executive Officer
Casey Hoyt was appointed Chief Executive Officer of Viemed Healthcare in December 2017. He is committed to the company's patient-centric focus and "live your life" mission. A long-time advocate for helping patients through clinical excellence, education, and technology, Hoyt co-founded Viemed subsidiaries, Sleep Management, LLC, and Home Sleep Delivered, LLC in 2006, prior to Viemed Healthcare's evolution in 2012. He has also led numerous other successful businesses throughout his career, including a global trade show display and event marketing services company.
Trae Fitzgerald, Chief Financial Officer
Trae Fitzgerald serves as the Chief Financial Officer and Principal Accounting Officer of Viemed Healthcare, a position he has held since November 2017. As CFO, his total compensation in 2024 was reported as $872,178.
Todd Zehnder, Chief Operating Officer
Todd Zehnder has been Viemed's Chief Operating Officer since 2017. Throughout his tenure with the company, he has also held roles as Vice President of Finance and Chief Strategy Officer. A Certified Public Accountant, Zehnder began his career at KPMG. He also held multiple senior executive positions, including Chief Operating Officer and Chief Financial Officer, for 15 years at PetroQuest Energy Inc., an NYSE-listed company.
Michael Moore, President
Michael Moore is the President of Viemed Healthcare. He was involved in the founding of Viemed Healthcare in 2006.
Michael Freeman, Chief Business Development Officer
Michael Freeman joined Viemed Healthcare as Chief Business Development Officer in August 2022. Before his role at Viemed, Freeman served for nearly 20 years as Senior Vice President of Corporate Development at LHC Group, Inc. In this capacity, he was responsible for new partnership and acquisition activities, including identifying targets, managing due diligence, planning integration, and negotiating agreements. He was involved in over 150 acquisition and partnership transactions at LHC. Collectively, with Jeremy Trahan, he was integrally involved in over 100 transactions at LHC Group valued at approximately $1.9 billion.
AI Analysis | Feedback
The key risks to Viemed Healthcare (VMD) are primarily centered around the highly regulated healthcare environment, the reliance on third-party medical equipment, and the inherent challenges of in-home medical device usage.
- Government Regulation and Reimbursement Policies: Viemed Healthcare operates within a complex and extensively regulated U.S. healthcare system. The company faces ongoing exposure to U.S. healthcare reform, anti-kickback statutes, and other compliance risks. A significant portion of Viemed's revenue comes from Medicare and Medicaid, accounting for 40% and 43% respectively in 2025 and 2024. Any reduction or elimination of coverage or reimbursement for their products by these government programs could lead to similar reductions by commercial third-party payors, thereby adversely affecting the business and its financial results. Durable medical equipment (DME) companies like Viemed are subject to strict federal oversight by organizations such as the U.S. Department of Health and Human Services' Office of Inspector General (HHS-OIG) and the Centers for Medicare and Medicaid Services (CMS), with common violations involving complex billing and marketing practices.
- Product Recalls and Supply Chain Dependence: Viemed distributes and sells specific medical devices, such as Royal Philips BiPAP and CPAP devices and ventilators. A voluntary recall of such products due to potential health risks, as occurred with Philips devices, can have an adverse impact on Viemed's business, reputation, financial performance, and future prospects. Furthermore, there is a risk that vendors may not always be able to provide the necessary equipment to satisfy demand in an emerging market, which could affect Viemed's ability to serve patients.
- Usability Challenges and Risks of Home Medical Devices: A significant hazard for Viemed's business model, which focuses on in-home care, stems from the usability challenges and inherent risks associated with medical devices used in residential settings. Medical devices like ventilators, often designed for professional use in clinical environments, can be complex for patients and non-professional caregivers to operate safely and effectively at home. ECRI, a non-profit organization focused on healthcare safety, identified the use of medical devices in the home as the top health technology safety hazard for 2024, citing risks from insufficient training for users, potential misuse or malfunction, and the possibility of undetected or unreported errors.
AI Analysis | Feedback
The emergence of direct-to-consumer (DTC) models for durable medical equipment, particularly for sleep apnea devices such as PAP machines, poses a clear threat. These models, often facilitated by online telehealth consultations and manufacturer partnerships, allow patients to obtain equipment directly, bypassing traditional DME providers like Viemed Healthcare. This shift in the distribution and service delivery model can lead to reduced reliance on intermediaries, impacting Viemed's market share and revenue stream in its sleep apnea management segment.
AI Analysis | Feedback
Viemed Healthcare, Inc. (VMD) operates within several significant addressable markets related to in-home durable medical equipment (DME) and post-acute respiratory healthcare services in the United States.
Addressable Markets for Viemed Healthcare's Main Products and Services:
- U.S. Respiratory Durable Medical Equipment (DME) Market: This market, which directly encompasses many of Viemed's offerings such as oxygen therapy, non-invasive home ventilators, and connected PAP machines, was valued at approximately USD 4.01 billion in 2025. It is projected to grow to about USD 5.89 billion by 2033, with a compound annual growth rate (CAGR) of 4.93% from 2026 to 2033. Respiratory and sleep devices constitute approximately 35% of the total U.S. DME market revenue.
- U.S. Durable Medical Equipment (DME) Market (Overall): The broader U.S. durable medical equipment market was valued at an estimated USD 43.58 billion in 2024 and is predicted to reach around USD 79.57 billion by 2034, expanding at a CAGR of 6.21% from 2025 to 2034. This market is projected to exceed USD 110 billion by 2028.
- Sleep Apnea Devices Market (North America/Global): Viemed Healthcare provides sleep apnea management solutions and in-home sleep apnea testing. The global sleep apnea devices market was estimated at USD 4.5 billion in 2023 and is projected to reach USD 6.9 billion by 2030, growing at a CAGR of 6.2% from 2024 to 2030. North America held the largest share of this market, accounting for 48.1% in 2023. Another report indicated the global market for sleep apnea devices was USD 5.40 billion in 2024 and is expected to grow to USD 10.2 billion by 2033, with a CAGR of 7.32% from 2026 to 2033. North America also consistently dominated the sleep apnea devices market in 2023 and 2024.
- COPD Addressable Market (Viemed's Niche): Viemed Healthcare specifically addresses a niche within the COPD market. It is estimated that approximately 1.25 million treatable patients in the U.S. suffer from Stage 4 COPD with chronic respiratory failure, representing an estimated USD 20 billion in potential revenue for providers like Viemed.
AI Analysis | Feedback
Viemed Healthcare, Inc. (VMD) is expected to drive future revenue growth over the next two to three years through several key initiatives and market trends:
- Expansion of Sleep Therapy Services: Viemed Healthcare is experiencing significant growth in its sleep therapy segment, particularly with PAP (Positive Airway Pressure) therapy patients and resupply services. The company reported a 62% year-over-year increase in PAP therapy patient count and a 49% rise in sleep resupply patients in 2025. This area is considered a crucial and accelerating growth driver, supported by a large underdiagnosed obstructive sleep apnea market and increasing clinical awareness.
- Growth in Maternal Health: The acquisition of Lehan's Medical Equipment in 2025 marked Viemed Healthcare's expansion into maternal health. This segment contributed approximately $9 million to the company's revenue in 2025 and is projected to become a more significant contributor as the company expands these services beyond the initial markets of the acquisition throughout 2026. This expansion also helps diversify the company's payer mix.
- Diversification of Home Medical Equipment (HME) Offerings: While traditionally strong in ventilation, Viemed Healthcare is actively diversifying its HME rental portfolio. The company has seen growth in other non-ventilator HME rentals, including oxygen and airway clearance therapies, alongside its sleep therapy devices. This strategic diversification aims to reduce reliance on any single product category and broaden the company's service offerings.
- Organic Growth through Market Expansion and Densification: Viemed Healthcare's strategy includes organic growth through both geographic expansion into new target markets and densifying its presence in existing markets. This approach focuses on increasing its patient base and strengthening its operational footprint across the United States.
- Strategic Acquisitions: The company maintains an active pipeline for mergers and acquisitions (M&A) to acquire complementary services and platforms that can leverage its existing national infrastructure, including payer relationships and clinical operations. The successful integration and positive contribution of the Lehan's acquisition serve as a testament to this inorganic growth strategy.
AI Analysis | Feedback
Share Repurchases
- Viemed Healthcare authorized a new share repurchase program through March 2027, allowing for the purchase of up to 1,930,131 common shares, representing approximately 5% of its total outstanding shares as of March 4, 2026.
- Across three prior share repurchase programs, Viemed returned approximately $26.3 million to shareholders by repurchasing about 4.5 million shares.
- A share repurchase program authorized in June 2025, for up to 1,976,441 shares, was fully completed by September 23, 2025, at a total cost of approximately $13.2 million.
Outbound Investments
- Viemed Healthcare completed the acquisition of Lehan's Medical Equipment in 2025, which contributed to an increase in net revenues for the year.
- The company views selective acquisitions as an opportunistic component of its broader capital allocation framework, alongside investment in organic growth.
Capital Expenditures
- Net capital expenditures for the year ended December 31, 2025, totaled approximately $23.8 million.
- Net capital expenditures for the year ended December 31, 2024, totaled approximately $27.5 million.
- Viemed's capital allocation framework supports continued investment in organic growth and selective acquisitions.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Viemed Healthcare Earnings Notes | 12/16/2025 | |
| Viemed Healthcare Stock Jump Looks Great, But How Secure Is That Gain? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to VMD.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 8.50 |
| Mkt Cap | 0.8 |
| Rev LTM | 537 |
| Op Inc LTM | 10 |
| FCF LTM | 13 |
| FCF 3Y Avg | -1 |
| CFO LTM | 54 |
| CFO 3Y Avg | 19 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 19.8% |
| Rev Chg 3Y Avg | 18.5% |
| Rev Chg Q | 18.8% |
| QoQ Delta Rev Chg LTM | 4.0% |
| Op Inc Chg LTM | 58.6% |
| Op Inc Chg 3Y Avg | 34.1% |
| Op Mgn LTM | 3.4% |
| Op Mgn 3Y Avg | 0.4% |
| QoQ Delta Op Mgn LTM | 1.1% |
| CFO/Rev LTM | 13.2% |
| CFO/Rev 3Y Avg | 7.0% |
| FCF/Rev LTM | 4.5% |
| FCF/Rev 3Y Avg | -1.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.8 |
| P/S | 1.8 |
| P/Op Inc | -4.7 |
| P/EBIT | 0.1 |
| P/E | 7.4 |
| P/CFO | 22.8 |
| Total Yield | 1.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -0.2% |
| D/E | 0.2 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -2.4% |
| 3M Rtn | 1.2% |
| 6M Rtn | -12.9% |
| 12M Rtn | -0.9% |
| 3Y Rtn | -9.5% |
| 1M Excs Rtn | -7.4% |
| 3M Excs Rtn | -7.2% |
| 6M Excs Rtn | -22.2% |
| 12M Excs Rtn | -26.3% |
| 3Y Excs Rtn | -90.5% |
Price Behavior
Price Behavior
| Market Price | $9.35 | |
| Market Cap ($ Bil) | 0.4 | |
| First Trading Date | 03/16/2018 | |
| Distance from 52W High | -7.0% | |
| 50 Days | 200 Days | |
| DMA Price | $9.44 | $7.73 |
| DMA Trend | up | up |
| Distance from DMA | -1.0% | 21.0% |
| 3M | 1YR | |
| Volatility | 50.7% | 38.6% |
| Downside Capture | 72.52 | 55.26 |
| Upside Capture | 95.03 | 78.62 |
| Correlation (SPY) | 14.8% | 25.0% |
VMD Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.60 | 1.01 | 0.80 | 0.80 | 0.93 | 0.72 |
| Up Beta | 0.04 | 0.23 | 0.19 | 0.71 | 1.33 | 0.64 |
| Down Beta | 6.76 | 0.18 | 0.47 | 0.47 | 0.75 | 0.59 |
| Up Capture | 76% | 185% | 182% | 157% | 85% | 42% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 13 | 26 | 40 | 71 | 128 | 364 |
| Down Capture | 378% | 133% | 56% | 54% | 77% | 98% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 9 | 16 | 23 | 51 | 111 | 366 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VMD | |
|---|---|---|---|---|
| VMD | 40.4% | 38.5% | 0.97 | - |
| Sector ETF (XLV) | 14.8% | 14.9% | 0.71 | 29.1% |
| Equity (SPY) | 27.4% | 12.1% | 1.71 | 24.7% |
| Gold (GLD) | 42.5% | 26.8% | 1.30 | -3.4% |
| Commodities (DBC) | 45.4% | 18.5% | 1.88 | -13.2% |
| Real Estate (VNQ) | 11.5% | 13.5% | 0.56 | 26.1% |
| Bitcoin (BTCUSD) | -21.4% | 41.7% | -0.47 | 2.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VMD | |
|---|---|---|---|---|
| VMD | 0.7% | 41.4% | 0.14 | - |
| Sector ETF (XLV) | 4.8% | 14.7% | 0.15 | 21.9% |
| Equity (SPY) | 13.6% | 17.1% | 0.63 | 25.8% |
| Gold (GLD) | 19.4% | 17.9% | 0.88 | 5.4% |
| Commodities (DBC) | 10.9% | 19.4% | 0.45 | 0.1% |
| Real Estate (VNQ) | 2.9% | 18.8% | 0.06 | 22.4% |
| Bitcoin (BTCUSD) | 7.8% | 55.9% | 0.35 | 12.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VMD | |
|---|---|---|---|---|
| VMD | 5.7% | 48.7% | 0.34 | - |
| Sector ETF (XLV) | 9.6% | 16.5% | 0.47 | 24.7% |
| Equity (SPY) | 15.5% | 17.9% | 0.74 | 28.5% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 4.9% |
| Commodities (DBC) | 8.3% | 17.9% | 0.38 | 7.6% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.21 | 22.7% |
| Bitcoin (BTCUSD) | 67.9% | 66.9% | 1.07 | 12.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/4/2026 | -7.5% | 0.0% | 6.1% |
| 11/5/2025 | -2.6% | 1.9% | 6.4% |
| 8/6/2025 | 7.9% | 13.6% | 6.7% |
| 3/10/2025 | 5.4% | 0.1% | -10.0% |
| 11/6/2024 | -1.5% | 0.1% | -5.7% |
| 8/7/2024 | 10.0% | 8.6% | 12.3% |
| 3/6/2024 | 6.5% | 1.1% | -9.4% |
| 11/1/2023 | 12.0% | 14.3% | 26.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 15 | 11 |
| # Negative | 9 | 4 | 8 |
| Median Positive | 7.2% | 3.1% | 7.3% |
| Median Negative | -3.7% | -4.8% | -8.4% |
| Max Positive | 18.2% | 30.4% | 40.5% |
| Max Negative | -14.2% | -22.1% | -25.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 03/04/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 03/10/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/06/2024 | 10-Q |
| 12/31/2023 | 03/06/2024 | 10-K |
| 09/30/2023 | 11/01/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 03/02/2023 | 10-K |
| 09/30/2022 | 11/01/2022 | 10-Q |
| 06/30/2022 | 08/02/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 312.00 Mil | 316.00 Mil | 320.00 Mil | 0.3% | Raised | Guidance: 315.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | 65.00 Mil | 67.00 Mil | 69.00 Mil | 0 | Affirmed | Guidance: 67.00 Mil for 2026 | |
| 2026 Net Capital Expenditures | 0.09 | 0.1 | 0.1 | -9.3% | -1.0% | Lowered | Guidance: 0.11 for 2026 |
Prior: Q4 2025 Earnings Reported 3/4/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net Revenue | 310.00 Mil | 315.00 Mil | 320.00 Mil | 15.8% | Higher New | Guidance: 272.00 Mil for 2025 | |
| 2026 Adjusted EBITDA | 65.00 Mil | 67.00 Mil | 69.00 Mil | 9.8% | Higher New | Guidance: 61.00 Mil for 2025 | |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Moore, Michael | President | by Moore Faster LLC | Sell | 3202026 | 8.77 | 65,000 | 570,050 | 13,907,571 | Form |
| 2 | Moore, Michael | President | by Moore Faster LLC | Sell | 3202026 | 9.21 | 40,232 | 370,537 | 15,203,979 | Form |
| 3 | Moore, Michael | President | by Moore Faster LLC | Sell | 3202026 | 9.42 | 31,570 | 297,389 | 15,929,634 | Form |
| 4 | Cambre, Jerome | Vice President of Sales | Direct | Sell | 8142025 | 7.32 | 4,880 | 35,737 | 616,551 | Form |
| 5 | Moore, Michael | President | Direct | Sell | 8132025 | 7.33 | 50,090 | 367,160 | 926,094 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.